The markets traded higher during the midday with the Dow rising 24 points to 14,999 as June auto sales climbed. Nasdaq gained 6 points to 3441.

On the upside

Mad Money’s Jim Cramer rated Celldex Therapeutics (Nasdaq: CLDX) a Buy. 

AcelRx Pharmaceuticals (Nasdaq: ACRX) was added to the Russell 3000 Index and the Russell Global Index on July 1, 2013. 

Celsion (Nasdaq: CLSN) reappointed Jeffrey W. Church to the position of chief financial officer.

On the downside

Hudson Technologies (Nasdaq: HDSN) reported lower preliminary second quarter earnings and revenue.

The proposed 9.4% cut to Medicare reimbursements for dialysis patients sent shares of Fresenius Medical Care (NYSE: FMS) tumbling.

China launched an antitrust violation investigation into foreign infant milk formula companies Abbott Laboratories (NYSE: ABT), Danone, Mead Johnson Nutrition (NYSE: MJN) and Nestle.

In the broad market, advancing issues outpaced decliners by a margin of nearly 6 to 5 on the NYSE and by nearly 5 to 4 on Nasdaq. The broader S&P 500 index added 4 points to 1618.